European journal of anaesthesiology. Supplement
-
Eur J Anaesthesiol Suppl · Sep 1995
Randomized Controlled Trial Clinical TrialEvaluation of neuromuscular effects and antagonism of rocuronium bromide: a preliminary report.
Twenty ASA I-II patients received either 2 or 3 x ED95 doses of rocuronium bromide during nitrous oxide, oxygen, propofol, fentanyl-based anaesthesia. The mean times to maximum block were 98 s and 74 s and the mean duration of clinical relaxation (recovery to 25% T1) was 35 min and 46 min following 620 micrograms kg-1 and 930 micrograms kg-1, respectively. Neuromuscular blockade was antagonized with either neostigmine or edrophonium from a twitch height of 25%. Although there was no significant difference between the recovery times neostigmine appeared to give more consistent antagonism of rocuronium-induced blockade.
-
Eur J Anaesthesiol Suppl · Sep 1995
Randomized Controlled Trial Comparative Study Clinical TrialRocuronium bromide: time-course of action in underweight, normal weight, overweight and obese patients.
The duration of action and recovery of 0.6 mg kg-1 rocuronium in underweight, normal weight, overweight and obese patients were investigated. Forty-eight patients were divided into four groups, according to their body mass index, and were given 0.6 mg kg-1 rocuronium. ⋯ The duration 25% was slightly prolonged in the obese patients (31.5 (21.0-61.0) min) when compared to the underweight (25.0 (15.0-37.0) min), normal weight (26.0 (20.0-36.0) min) and overweight (27.0 (19.0-35.0) min) patients. No differences were observed in spontaneous (9.5-12.5 min) and induced (2.5-3.5 min) recovery.
-
Eur J Anaesthesiol Suppl · Sep 1995
Randomized Controlled Trial Comparative Study Clinical TrialRocuronium- and mivacurium-induced neuromuscular block and intubating conditions: a comparison with vecuronium.
The time-course of action after an initial 2 x ED90 dose and after maintenance doses of 0.5 x ED90, and intubating conditions at 90 s after a 2 x ED90 dose following rocuronium, vecuronium and mivacurium were evaluated in anaesthetized adult patients. Neuromuscular measurements were performed with mechanomyography. ⋯ At 90 s, intubating conditions were significantly better in the rocuronium group than in the vecuronium or mivacurium group. Mivacurium offered a significantly faster recovery of neuromuscular block following the 2 x ED90 dose and following an average of 45 min of clinical muscle relaxation (single twitch response < or = 25%) compared to rocuronium and vecuronium: clinical duration 13 (4), 28 (9) and 33 (9) min, respectively, and recovery time from 25 to 75% recovery of the single twitch response: 6 (2), 11 (4) and 14 (7) min, respectively.
-
Eur J Anaesthesiol Suppl · Sep 1995
Randomized Controlled Trial Clinical TrialDose-response, time-course of action and recovery of rocuronium bromide in children during halothane anaesthesia.
Two groups of children, aged 1-4 years (n = 28) and 5-10 years (n = 28), respectively, received at random one of four doses of rocuronium (0.12, 0.17, 0.22 or 0.27 mg kg-1). When maximum block was obtained, further rocuronium to a total dose of 0.5 mg kg-1 was given. At a spontaneous T1 recovery of 25% the block was reversed with atropine and neostigmine in half the patients. ⋯ Neostigmine administration reduced recovery time by approximately half to two-thirds. MAP was not influenced by rocuronium. Following the injection of rocuronium in the younger age group there was a 15% increase in heart rate compared to a 10% increase in the age group 5-10 years.
-
Eur J Anaesthesiol Suppl · Sep 1995
ReviewOnset time and evaluation of intubating conditions: rocuronium in perspective.
The customary methods for assessment of intubating conditions, namely the onset time in the adductor pollicis muscle and qualitative rating scales of the conditions at intubation, are unsatisfactory. The onset time of neuromuscular block in the adductor pollicis is not a meaningful, quantifiable endpoint, defining optimal intubating conditions. ⋯ Clinical studies simulating rapid sequence induction in elective patients indicate that rocuronium 0.9 mg kg-1 may be suitable for crash intubation. This, however, needs to be confirmed in emergency cases.